|
POROKERATOSIS 7, MULTIPLE TYPES
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
[Analysis of clinical and genetic features of nine patients with disseminated superfacial actinic porokeratosis].
|
28777842 |
2017 |
|
POROKERATOSIS 7, MULTIPLE TYPES
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Genomic variations of the mevalonate pathway in porokeratosis.
|
26202976 |
2015 |
|
POROKERATOSIS 7, MULTIPLE TYPES
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Genomic variations of the mevalonate pathway in porokeratosis.
|
26202976 |
2015 |
|
POROKERATOSIS 7, MULTIPLE TYPES
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Human mevalonate diphosphate decarboxylase: characterization, investigation of the mevalonate diphosphate binding site, and crystal structure.
|
18823933 |
2008 |
|
POROKERATOSIS 7, MULTIPLE TYPES
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
POROKERATOSIS 7, MULTIPLE TYPES
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Porokeratosis, Linear
|
0.320 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Second-Hit, Postzygotic PMVK and MVD Mutations in Linear Porokeratosis.
|
30942823 |
2019 |
|
Porokeratosis, Linear
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Second-Hit, Postzygotic PMVK and MVD Mutations in Linear Porokeratosis.
|
30942823 |
2019 |
|
Porokeratosis, Linear
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Patients with disseminated superficial actinic porokeratosis (DSAP) and linear porokeratosis (LP) exhibit monoallelic germline mutations in genes encoding mevalonate pathway enzymes, such as MVD or MVK.
|
31207227 |
2019 |
|
Porokeratosis, Disseminated Superficial Actinic
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
Patients with disseminated superficial actinic porokeratosis (DSAP) and linear porokeratosis (LP) exhibit monoallelic germline mutations in genes encoding mevalonate pathway enzymes, such as MVD or MVK.
|
31207227 |
2019 |
|
Porokeratosis, Disseminated Superficial Actinic
|
0.310 |
GermlineCausalMutation
|
disease |
ORPHANET |
Genomic variations of the mevalonate pathway in porokeratosis.
|
26202976 |
2015 |
|
Porokeratosis
|
0.120 |
GeneticVariation
|
disease |
BEFREE |
Clonal Expansion of Second-Hit Cells with Somatic Recombinations or C>T Transitions Form Porokeratosis in MVD or MVK Mutant Heterozygotes.
|
31207227 |
2019 |
|
Porokeratosis
|
0.120 |
Biomarker
|
disease |
BEFREE |
Mutation of four genes in this pathway, including mevalonate kinase, phosphomevalonate kinase, mevalonate diphosphate decarboxylase and farnesyl diphosphate synthase, have demonstrated to be responsible for porokeratosis (PK).
|
28765912 |
2017 |
|
Porokeratosis
|
0.120 |
Biomarker
|
disease |
HPO |
|
|
|
|
Squamous cell carcinoma
|
0.110 |
Biomarker
|
disease |
BEFREE |
The TSP-1 intensities were significantly higher and the MVD counts lower in the groups of normal and LSIL epithelium than in those with HSIL and SCC epithelium.
|
15000492 |
2004 |
|
Squamous cell carcinoma
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The RGD-4R-MPD/TTB NPs-mediated PDT in multiple xenograft tumor models disclose that the growth of cervical, prostate, and ovarian cancers in mice can be effectively inhibited.
|
31820925 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We used immunohistochemistry and morphometry to evaluate the amount of tumor staining for cellular proliferation (Ki-67), microvascular density (CD34-MVD), and D2-40 lymphovascular density.
|
30031097 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Significant reduction in tumor proliferation index and MVD, as well as significant increase in apoptosis, were observed for the treated tumor sections.Further, the intravenous (i.v.) administration of PSPLBC enhanced the tumor US-contrast by 2-fold as compared to SonoVue.
|
29422676 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor PS and K<sup>trans</sup> values were correlated with CD105-MVD (r=0.644, P<0.001; r=0.683, P<0.001).
|
28034567 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, tumors with RBP2-positive expression showed significantly higher intratumoral MVD than those with RBP2-negative expression (P=0.000).
|
28582381 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also found that ADN-9 showed stronger abilities than AD in shrinking tumors, suppressing the invasion and metastasis of H22 cells, decreasing the MVD and promoting tumor cell apoptosis in subcutaneous xenograft of mice.
|
28438631 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CCL18 is a better biomarker than MVD in determining whether the tumor is malignant and the severity of malignancy of breast cancer.
|
26294068 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A significant positive correlation was found between the expression of Mortalin and Vimentin, and tumors with high expression of Mortalin had a tendency to higher MVD compared to those with low expression of Mortalin.
|
24190572 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Of the 102 stage I NSCLC specimens analyzed, high RBP2 protein expression is closely associated with tumor size (P = 0.030), high HIF-1α expression (P = 0.028), high VEGF expression (P = 0.048), increased tumor angiogenesis (P = 0.033) and poor prognosis (P = 0.037); high MVD was associated with high HIF-1α expression (P = 0.034), high VEGF expression (P = 0.001) and poor prognosis (P = 0.040).
|
25162518 |
2014 |